Search

Displaying results 1561 - 1570 of 7540 in total
  1. Drug

    Urea C-14

    go.drugbank.com/drugs/DB09513
    ApprovedInvestigational

    To detect H. pylori, urea labeled with 14C is swallowed by the patient. … Both forms can be used within the Urea Breath Test, however some may prefer 13C as it is non-radioactive compared to 14C, which may be preferable in pregnant women and children.

  2. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    cells that the body is no longer able to produce insulin on its own. … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able

  3. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … relief was observed to be 8 hours compared to 36 hours for the placebo treatment.

    Categories: Analgesics, Non-Narcotic
  4. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    The composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin. … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.

    Products: OCTAPLAS Blood Group O
  5. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued. … Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma.

  6. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.

  7. Drug

    Bupropion

    go.drugbank.com/drugs/DB01156
    ApprovedInvestigational

    [A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved … [A178789] Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical

  8. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [A247265] On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory

  9. Drug

    Calfactant

    go.drugbank.com/drugs/DB06415
    ApprovedInvestigational

    Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.

  10. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] It was developed by Global Blood Therapeutics, Inc. … to 20 million others worldwide.